Keith R. Leonard
Known title: DirectorCIK: 0001416180
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Intuitive Surgical Prepares for Q3 Earnings Amid Growth and Competition. Intuitive Surgical is approaching its Q3 earnings release, with analysts noting continued double‑digit revenue growth and expanding procedure volumes. At the same time, new robotic competitors are entering the market, prompting discussion of the company's current valuation multiples. The stock has shown strong price momentum, reflected in a relatively high RSI and recent touches near its 200‑day moving average.
Transaction History
| ARQT | ▲ Buy | Grant | 5,778 | $0 | 6/5/2026 | View on chart |
| ISRG | ▲ Buy | Option Exercise | 531 | $0 | 4/30/2026 | View on chart |
| ARQT | ▲ Buy | Option Exercise | 27,052 | $233K | 3/2/2026 | View on chart |
| ARQT | ▲ Buy | Option Exercise | 12,220 | $92K | 3/2/2026 | View on chart |
| ARQT | ▼ Sell | Open Market | 39,272 | $997K | 3/2/2026 | View on chart |
| ISRG | ▼ Sell | Other | 369 | $0 | 1/29/2026 | View on chart |
| ARQT | ▼ Sell | Gift | 4,312 | $0 | 11/13/2025 | View on chart |
| ISRG | ▼ Sell | Gift | 1,606 | $0 | 11/12/2025 | View on chart |
| ARQT | ▲ Buy | Grant | 7,609 | $0 | 6/12/2025 | View on chart |
| ISRG | ▲ Buy | Option Exercise | 739 | $0 | 4/25/2025 | View on chart |
| ARQT | ▲ Buy | Grant | 10,139 | $0 | 6/14/2024 | View on chart |
| ISRG | ▲ Buy | Option Exercise | 569 | $0 | 4/25/2024 | View on chart |
| ISRG | ▼ Sell | Gift | 2,547 | $0 | 2/15/2024 | View on chart |
| ARQT | ▲ Buy | Grant | 4,375 | $0 | 5/31/2023 | View on chart |
| ISRG | ▲ Buy | Option Exercise | 482 | $0 | 4/27/2023 | View on chart |
| ARQT | ▲ Buy | Grant | 4,312 | $0 | 6/1/2022 | View on chart |
| ISRG | ▲ Buy | Option Exercise | 555 | $0 | 4/22/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
ARQT Highlights New ZORYVE Data, Wins Beauty Award, Faces Downgrade
Arcutis Biotherapeutics presented fresh clinical data for its topical drug ZORYVE at the EADV and Fall Clinical conferences, adding real‑world evidence on its use for inflammatory skin conditions. The company also received a 2026 Marie Claire Beauty Award for ZORYVE, highlighting its potential beyond dermatology. Meanwhile, analysts have downgraded the stock, citing a shrinking valuation multiple. These developments suggest the market is reassessing the company’s growth prospects.
ARQT Highlights New ZORYVE Data, Wins Beauty Award, Faces Downgrade. Arcutis Biotherapeutics presented fresh clinical data for its topical drug ZORYVE at the EADV and Fall Clinical conferences, adding real‑world evidence on its use for inflammatory skin conditions. The company also received a 2026 Marie Claire Beauty Award for ZORYVE, highlighting its potential beyond dermatology. Meanwhile, analysts have downgraded the stock, citing a shrinking valuation multiple. These developments suggest the market is reassessing the company’s growth prospects.